Imugene
Imugene Limited (ASX: IMU) is a biotechnology company focused on the development of immunotherapies for the treatment of cancer. The company operates in the biopharmaceutical sector, primarily targeting the development of innovative cancer treatments that harness the body’s immune system to fight tumors. Imugene’s core products include oncolytic virotherapy and other immunotherapy candidates designed to enhance the immune response against cancer cells.